A review of combined treatments for melasma involving energy‐based devices and proposed pathogenesis‐oriented combinations
Background Melasma is an acquired disorder of hyperpigmentation, affecting a million individuals worldwide. Energy‐based devices (EBDs) employed to treat melasma include various types of lasers, intense pulsed light (IPL), and radiofrequency (RF). Recent studies have attempted to address recalcitran...
Saved in:
| Published in | Journal of cosmetic dermatology Vol. 21; no. 2; pp. 461 - 472 |
|---|---|
| Main Authors | , , , , , , , , , , , |
| Format | Journal Article |
| Language | English |
| Published |
England
01.02.2022
|
| Subjects | |
| Online Access | Get full text |
| ISSN | 1473-2130 1473-2165 1473-2165 |
| DOI | 10.1111/jocd.14110 |
Cover
| Abstract | Background
Melasma is an acquired disorder of hyperpigmentation, affecting a million individuals worldwide. Energy‐based devices (EBDs) employed to treat melasma include various types of lasers, intense pulsed light (IPL), and radiofrequency (RF). Recent studies have attempted to address recalcitrant and recurring melasma by combining energy‐based devices with topical or oral medications.
Objective
This article reviews EBDs‐based augmented treatment for melasma and suggests practical pathogenesis‐oriented treatment regimens. Treatment algorithms are proposed to address various components of melasma.
Methods
A systematic PubMed search was conducted acquiring information from various studies on combination treatments of melasma involving EBDs.
Results
The 286 retrieved articles were filtered by title to contain at least one type of energy‐based modality such as laser, IPL, or RF along with at least one other treatment method. Based on their subject matter, combinations were further categorized into the subheadings: laser plus medication, laser plus laser, and IPL‐ and RF‐containing treatment methods.
Conclusion
There are many energy‐based combination treatments that have been explored for mitigation of melasma including laser therapy with medication, multi‐laser therapies, IPL, RF, and microneedling devices. Melasma is an exceedingly difficult condition to treat, however, choosing the appropriate tailor‐made treatment combination can improve the final outcome. |
|---|---|
| AbstractList | Melasma is an acquired disorder of hyperpigmentation, affecting a million individuals worldwide. Energy-based devices (EBDs) employed to treat melasma include various types of lasers, intense pulsed light (IPL), and radiofrequency (RF). Recent studies have attempted to address recalcitrant and recurring melasma by combining energy-based devices with topical or oral medications.BACKGROUNDMelasma is an acquired disorder of hyperpigmentation, affecting a million individuals worldwide. Energy-based devices (EBDs) employed to treat melasma include various types of lasers, intense pulsed light (IPL), and radiofrequency (RF). Recent studies have attempted to address recalcitrant and recurring melasma by combining energy-based devices with topical or oral medications.This article reviews EBDs-based augmented treatment for melasma and suggests practical pathogenesis-oriented treatment regimens. Treatment algorithms are proposed to address various components of melasma.OBJECTIVEThis article reviews EBDs-based augmented treatment for melasma and suggests practical pathogenesis-oriented treatment regimens. Treatment algorithms are proposed to address various components of melasma.A systematic PubMed search was conducted acquiring information from various studies on combination treatments of melasma involving EBDs.METHODSA systematic PubMed search was conducted acquiring information from various studies on combination treatments of melasma involving EBDs.The 286 retrieved articles were filtered by title to contain at least one type of energy-based modality such as laser, IPL, or RF along with at least one other treatment method. Based on their subject matter, combinations were further categorized into the subheadings: laser plus medication, laser plus laser, and IPL- and RF-containing treatment methods.RESULTSThe 286 retrieved articles were filtered by title to contain at least one type of energy-based modality such as laser, IPL, or RF along with at least one other treatment method. Based on their subject matter, combinations were further categorized into the subheadings: laser plus medication, laser plus laser, and IPL- and RF-containing treatment methods.There are many energy-based combination treatments that have been explored for mitigation of melasma including laser therapy with medication, multi-laser therapies, IPL, RF, and microneedling devices. Melasma is an exceedingly difficult condition to treat, however, choosing the appropriate tailor-made treatment combination can improve the final outcome.CONCLUSIONThere are many energy-based combination treatments that have been explored for mitigation of melasma including laser therapy with medication, multi-laser therapies, IPL, RF, and microneedling devices. Melasma is an exceedingly difficult condition to treat, however, choosing the appropriate tailor-made treatment combination can improve the final outcome. Background Melasma is an acquired disorder of hyperpigmentation, affecting a million individuals worldwide. Energy‐based devices (EBDs) employed to treat melasma include various types of lasers, intense pulsed light (IPL), and radiofrequency (RF). Recent studies have attempted to address recalcitrant and recurring melasma by combining energy‐based devices with topical or oral medications. Objective This article reviews EBDs‐based augmented treatment for melasma and suggests practical pathogenesis‐oriented treatment regimens. Treatment algorithms are proposed to address various components of melasma. Methods A systematic PubMed search was conducted acquiring information from various studies on combination treatments of melasma involving EBDs. Results The 286 retrieved articles were filtered by title to contain at least one type of energy‐based modality such as laser, IPL, or RF along with at least one other treatment method. Based on their subject matter, combinations were further categorized into the subheadings: laser plus medication, laser plus laser, and IPL‐ and RF‐containing treatment methods. Conclusion There are many energy‐based combination treatments that have been explored for mitigation of melasma including laser therapy with medication, multi‐laser therapies, IPL, RF, and microneedling devices. Melasma is an exceedingly difficult condition to treat, however, choosing the appropriate tailor‐made treatment combination can improve the final outcome. Melasma is an acquired disorder of hyperpigmentation, affecting a million individuals worldwide. Energy-based devices (EBDs) employed to treat melasma include various types of lasers, intense pulsed light (IPL), and radiofrequency (RF). Recent studies have attempted to address recalcitrant and recurring melasma by combining energy-based devices with topical or oral medications. This article reviews EBDs-based augmented treatment for melasma and suggests practical pathogenesis-oriented treatment regimens. Treatment algorithms are proposed to address various components of melasma. A systematic PubMed search was conducted acquiring information from various studies on combination treatments of melasma involving EBDs. The 286 retrieved articles were filtered by title to contain at least one type of energy-based modality such as laser, IPL, or RF along with at least one other treatment method. Based on their subject matter, combinations were further categorized into the subheadings: laser plus medication, laser plus laser, and IPL- and RF-containing treatment methods. There are many energy-based combination treatments that have been explored for mitigation of melasma including laser therapy with medication, multi-laser therapies, IPL, RF, and microneedling devices. Melasma is an exceedingly difficult condition to treat, however, choosing the appropriate tailor-made treatment combination can improve the final outcome. |
| Author | Isman Nelkenbaum, Gila Zur, Eyal Mashiah, Jacob Mehrabi, Joseph N. Wasim, Shehadeh Song Lim, Ting Artzi, Ofir Bar‐Ilan, Efrat Salameh, Fares Koren, Amir Zusmanovitch, Lior Horovitz, Tamir |
| Author_xml | – sequence: 1 givenname: Joseph N. orcidid: 0000-0002-2212-7075 surname: Mehrabi fullname: Mehrabi, Joseph N. organization: Tel‐Aviv University – sequence: 2 givenname: Efrat surname: Bar‐Ilan fullname: Bar‐Ilan, Efrat organization: Tel‐Aviv Sourasky Medical Center – sequence: 3 givenname: Shehadeh surname: Wasim fullname: Wasim, Shehadeh organization: Tel‐Aviv Sourasky Medical Center – sequence: 4 givenname: Amir orcidid: 0000-0001-8667-9330 surname: Koren fullname: Koren, Amir organization: Artzi Treatment and Research Center – sequence: 5 givenname: Lior surname: Zusmanovitch fullname: Zusmanovitch, Lior organization: Artzi Treatment and Research Center – sequence: 6 givenname: Fares surname: Salameh fullname: Salameh, Fares organization: Artzi Treatment and Research Center – sequence: 7 givenname: Gila surname: Isman Nelkenbaum fullname: Isman Nelkenbaum, Gila organization: Artzi Treatment and Research Center – sequence: 8 givenname: Tamir orcidid: 0000-0002-8018-0229 surname: Horovitz fullname: Horovitz, Tamir organization: Artzi Treatment and Research Center – sequence: 9 givenname: Eyal surname: Zur fullname: Zur, Eyal organization: Tel‐Mond – sequence: 10 givenname: Ting surname: Song Lim fullname: Song Lim, Ting organization: Clique Clinic – sequence: 11 givenname: Jacob surname: Mashiah fullname: Mashiah, Jacob organization: Tel‐Aviv Sourasky Medical Center – sequence: 12 givenname: Ofir orcidid: 0000-0003-1391-5843 surname: Artzi fullname: Artzi, Ofir email: benofir@gmail.com organization: Artzi Treatment and Research Center |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/33794033$$D View this record in MEDLINE/PubMed |
| BookMark | eNp9kU1OwzAQhS0E4n_DAZCXCKkwjhOnXaLyLyQ2sLYce1KMErvYaVE3iCNwRk6CS4AFQnhja_S9NzN-W2TVeYeE7DE4YukcP3ptjljOGKyQTZaXfJAxUaz-vDlskK0YHwFYOWLFOtngvBzlwPkmeTmhAecWn6mvqfZtZR0a2gVUXYuui7T2gbbYqNgqat3cN3PrJhQdhsni_fWtUjHxJllojFQ5Q6fBT_2yOFXdg58kMtqYSB9sMkz1vovqrHdxh6zVqom4-3Vvk_vzs7vx5eDm9uJqfHIz0DwbwYAJU2UaeM0FS-tkJRRlqQzySlcm01mdC8UBdMWE0oUBoaCCUuQCdKFxaPg2Oeh903RPM4ydbG3U2DTKoZ9FmRUwLBIvhgnd_0JnVYtGToNtVVjI7z9LAPSADj7GgLXUtvtcpwvKNpKBXMYil7HIz1iS5PCX5Nv1T5j18LNtcPEPKa9vx6e95gNDnKGf |
| CitedBy_id | crossref_primary_10_1111_jocd_15632 crossref_primary_10_1111_jocd_16006 crossref_primary_10_1007_s13555_022_00728_8 crossref_primary_10_3390_cosmetics10030086 crossref_primary_10_3390_medicina58070936 crossref_primary_10_1111_jocd_15834 |
| Cites_doi | 10.1111/jocd.12444 10.1097/01.dad.0000154419.18653.2e 10.1111/acel.12298 10.3109/09546634.2012.671911 10.1046/j.1524-4725.1999.08248.x 10.1111/j.1524-4725.2010.01523.x 10.1111/bjd.13424 10.1111/bjd.12536 10.1097/DSS.0000000000000304 10.1111/dsu.12060 10.1002/lsm.22518 10.5021/ad.2018.30.1.1 10.1016/j.jaad.2016.03.001 10.1097/DSS.0000000000000652 10.1097/MD.0000000000006897 10.1111/j.1600-0625.2009.01057.x 10.1080/09546634.2016.1187706 10.1007/s10103-016-1938-3 10.1002/lsm.22735 10.1111/j.1524-4725.2010.01849.x 10.1016/j.jaad.2005.12.039 10.1111/jocd.12751 10.3109/14764172.2013.769274 10.5021/ad.2019.31.2.133 10.22270/jddt.v9i2.2453 10.1080/09546634.2018.1516858 10.4103/0974-2077.118403 10.1111/j.1365-2230.2011.04150.x 10.3109/14764172.2010.487910 10.1097/DAD.0b013e3181ef2d45 10.1097/DSS.0000000000000057 10.3109/09546634.2013.848261 10.1111/j.1529-8019.2012.01530.x 10.1002/lsm.21156 10.1016/j.ijwd.2017.01.004 10.1186/1471-5945-12-18 10.1007/s10103-014-1608-2 10.4103/0378-6323.182806 10.1016/j.jdermsci.2007.01.009 10.5021/ad.2010.22.4.373 10.1080/14764172.2018.1427869 10.1046/j.0007-0963.2001.04556.x 10.1007/s10103-018-02698-w 10.29271/jcpsp.2018.01.13 10.1016/S0254-6272(09)60056-X 10.1111/jdv.12854 10.1046/j.1524-4725.2003.29009.x 10.3109/09546634.2015.1115812 10.1080/14764172.2016.1228980 10.1016/S0190-9622(81)70071-9 10.1080/14764172.2017.1342036 10.1016/j.bmc.2019.03.013 |
| ContentType | Journal Article |
| Copyright | 2021 Wiley Periodicals LLC. |
| Copyright_xml | – notice: 2021 Wiley Periodicals LLC. |
| DBID | AAYXX CITATION CGR CUY CVF ECM EIF NPM 7X8 |
| DOI | 10.1111/jocd.14110 |
| DatabaseName | CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed MEDLINE - Academic |
| DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) MEDLINE - Academic |
| DatabaseTitleList | MEDLINE - Academic MEDLINE |
| Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Medicine |
| EISSN | 1473-2165 |
| EndPage | 472 |
| ExternalDocumentID | 33794033 10_1111_jocd_14110 JOCD14110 |
| Genre | reviewArticle Journal Article Review |
| GroupedDBID | --- .3N .GA .Y3 05W 0R~ 1OC 24P 29K 31~ 33P 36B 3SF 4.4 50Y 50Z 52M 52O 52T 52U 52V 52W 53G 5GY 5HH 5VS 702 7PT 7X7 8-0 8-1 8-3 8-4 8-5 8FI 8FJ 930 A01 A03 AAESR AAEVG AAHHS AAKAS AANHP AAONW AASGY AAXRX AAZKR ABCUV ABDBF ABJNI ABPVW ABUWG ABXGK ACAHQ ACBWZ ACCFJ ACCMX ACCZN ACGFS ACMXC ACPOU ACRPL ACUHS ACXBN ACXQS ACYXJ ADBBV ADEOM ADIZJ ADKYN ADMGS ADNMO ADOZA ADPDF ADXAS ADZCM ADZMN AEEZP AEGXH AEIMD AENEX AEQDE AEUQT AFBPY AFEBI AFGKR AFKRA AFPWT AFZJQ AIACR AIURR AIWBW AJBDE ALAGY ALMA_UNASSIGNED_HOLDINGS ALUQN AMBMR AMYDB ASPBG ATUGU AVWKF AZBYB AZFZN AZVAB BAFTC BDRZF BENPR BFHJK BHBCM BMXJE BROTX BRXPI C45 CAG CCPQU COF CS3 D-6 D-7 D-E D-F D-I DCZOG DPXWK DRFUL DRMAN DRSTM EAD EAP EBD EBS EJD EMB EMK EMOBN ESX EX3 F00 F01 F04 F21 F5P FEDTE FUBAC FYUFA G-S G.N GODZA H.X HF~ HMCUK HVGLF HZ~ IHE KBYEO LATKE LEEKS LH4 LITHE LOXES LP6 LP7 LUTES LW6 LYRES MK4 MRFUL MRMAN MRSTM MSFUL MSMAN MSSTM MXFUL MXMAN MXSTM MY~ N04 N05 NF~ O66 O9- OIG OVD OVEED P2P P2W P2X P2Z P4B P4D PIMPY Q.N QB0 R.K ROL RX1 SUPJJ SV3 TEORI TUS UB1 UKHRP V8K W8V W99 WBKPD WHWMO WIH WIJ WIK WOHZO WOW WVDHM YFH YUY ZZTAW ~IA ~WT AAYXX AGQPQ CITATION PHGZM PHGZT CGR CUY CVF ECM EIF NPM 7X8 AAMMB AEFGJ AGXDD AIDQK AIDYY |
| ID | FETCH-LOGICAL-c3290-16db2c03f361130270577ade3bcbd2c2f46a300cb16ac5d06a0b076460c5ce8d3 |
| ISSN | 1473-2130 1473-2165 |
| IngestDate | Fri Jul 11 05:45:38 EDT 2025 Wed Feb 19 02:27:52 EST 2025 Thu Apr 24 22:59:51 EDT 2025 Tue Jul 01 02:37:39 EDT 2025 Wed Jan 22 16:27:29 EST 2025 |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 2 |
| Language | English |
| License | 2021 Wiley Periodicals LLC. |
| LinkModel | OpenURL |
| MergedId | FETCHMERGED-LOGICAL-c3290-16db2c03f361130270577ade3bcbd2c2f46a300cb16ac5d06a0b076460c5ce8d3 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 ObjectType-Review-3 content type line 23 |
| ORCID | 0000-0003-1391-5843 0000-0002-2212-7075 0000-0002-8018-0229 0000-0001-8667-9330 |
| PMID | 33794033 |
| PQID | 2508564668 |
| PQPubID | 23479 |
| PageCount | 0 |
| ParticipantIDs | proquest_miscellaneous_2508564668 pubmed_primary_33794033 crossref_citationtrail_10_1111_jocd_14110 crossref_primary_10_1111_jocd_14110 wiley_primary_10_1111_jocd_14110_JOCD14110 |
| ProviderPackageCode | CITATION AAYXX |
| PublicationCentury | 2000 |
| PublicationDate | February 2022 2022-02-00 2022-Feb 20220201 |
| PublicationDateYYYYMMDD | 2022-02-01 |
| PublicationDate_xml | – month: 02 year: 2022 text: February 2022 |
| PublicationDecade | 2020 |
| PublicationPlace | England |
| PublicationPlace_xml | – name: England |
| PublicationTitle | Journal of cosmetic dermatology |
| PublicationTitleAlternate | J Cosmet Dermatol |
| PublicationYear | 2022 |
| References | 2010; 12 2017; 3 2010; 19 2017; 49 2015; 30 2016; 75 2016; 31 2013; 169 2014; 25 2019; 18 2005; 27 2012; 12 2013; 6 2015; 173 2010; 22 2013; 15 2002; 146 2015; 41 2016; 42 2019; 27 2014; 14 2018; 30 2016; 82 2012; 25 2010; 9 2018; 28 2019; 9 2015; 6 2019; 3 2010; 36 2019; 31 2019; 30 2006; 54 2017; 28 2019; 34 1981; 4 1999; 25 2011; 33 2011; 37 2011; 36 2014; 40 2018; 20 2009; 29 2018; 17 2017; 96 2015; 27 2013; 39 2015; 29 2017; 19 2003; 29 2018; 11 2012; 44 2007; 46 e_1_2_8_28_1 e_1_2_8_24_1 e_1_2_8_47_1 e_1_2_8_26_1 e_1_2_8_49_1 e_1_2_8_3_1 e_1_2_8_5_1 e_1_2_8_7_1 e_1_2_8_9_1 e_1_2_8_43_1 e_1_2_8_22_1 e_1_2_8_45_1 e_1_2_8_41_1 e_1_2_8_17_1 e_1_2_8_19_1 e_1_2_8_13_1 e_1_2_8_36_1 e_1_2_8_15_1 e_1_2_8_38_1 e_1_2_8_57_1 Barolet D (e_1_2_8_59_1) 2018; 11 Kaur ABM (e_1_2_8_53_1) 2019; 3 e_1_2_8_32_1 e_1_2_8_55_1 e_1_2_8_11_1 e_1_2_8_34_1 Trelles MA (e_1_2_8_20_1) 2010; 9 e_1_2_8_51_1 e_1_2_8_30_1 e_1_2_8_29_1 e_1_2_8_25_1 e_1_2_8_46_1 e_1_2_8_27_1 e_1_2_8_48_1 e_1_2_8_2_1 e_1_2_8_4_1 e_1_2_8_6_1 e_1_2_8_8_1 e_1_2_8_21_1 e_1_2_8_42_1 e_1_2_8_23_1 e_1_2_8_44_1 Draelos ZD (e_1_2_8_18_1) 2011; 37 e_1_2_8_40_1 e_1_2_8_39_1 e_1_2_8_14_1 e_1_2_8_35_1 e_1_2_8_16_1 e_1_2_8_37_1 Elfar N (e_1_2_8_58_1) 2015; 6 e_1_2_8_10_1 e_1_2_8_31_1 Cameli N (e_1_2_8_50_1) 2014; 40 e_1_2_8_56_1 e_1_2_8_12_1 e_1_2_8_33_1 e_1_2_8_54_1 e_1_2_8_52_1 |
| References_xml | – volume: 40 start-page: 842 issue: 8 year: 2014 end-page: 850 article-title: Combination treatment of low‐fluence 1,064‐nm Q‐switched Nd: YAG laser with novel intense pulse light in Korean melasma patients: a prospective, randomized, controlled trial publication-title: Dermatol Surg – volume: 14 start-page: 67 issue: 1 year: 2014 end-page: 77 article-title: Granzyme B mediates both direct and indirect cleavage of extracellular matrix in skin after chronic low‐dose ultraviolet light irradiation publication-title: Aging Cell – volume: 42 start-page: 556 issue: 4 year: 2016 end-page: 559 article-title: Long‐pulsed dye laser of 595 nm in combination with pigment‐specific modalities for a patient exhibiting increased vascularity within lesions of melasma publication-title: Dermatol Surg – volume: 169 start-page: 41 year: 2013 end-page: 56 article-title: Facial hyperpigmentation: causes and treatment publication-title: Br J Dermatol – volume: 19 start-page: 383 issue: 7 year: 2017 end-page: 390 article-title: A split‐face, investigator‐blinded comparative study on the efficacy and safety of Q‐switched Nd:YAG laser plus microneedling with vitamin C versus Q‐switched Nd:YAG laser for the treatment of recalcitrant melasma publication-title: J Cosmet Laser Ther – volume: 9 start-page: 420 issue: 2 year: 2019 end-page: 427 article-title: Potential benefits of phytochemicals for treatment of hyperpigmentation publication-title: J Drug Delivery Therapeutics – volume: 27 start-page: 2499 issue: 12 year: 2019 end-page: 2507 article-title: Tyrosinase inhibitory study of flavonolignans from the seeds of Silybum marianum (Milk thistle) publication-title: Bioorg Med Chem – volume: 27 start-page: 96 issue: 2 year: 2005 end-page: 101 article-title: Light microscopic, immunohistochemical, and ultrastructural alterations in patients with melasma publication-title: Am J Dermatopathol – volume: 37 start-page: 126 issue: 1 year: 2011 end-page: 127 article-title: Low‐fluence Q‐switched neodymium‐doped yttrium aluminum garnet laser for melasma with pre‐ or post‐treatment triple combination cream publication-title: Dermatol Surg – volume: 44 start-page: 117 issue: 2 year: 2012 end-page: 124 article-title: Successful treatment of melasma using a combination of microdermabrasion and Q‐switched Nd:YAG lasers publication-title: Lasers Surg Med – volume: 4 start-page: 698 issue: 6 year: 1981 end-page: 710 article-title: Melasma: A clinical, light microscopic, ultrastructural, and immunofluorescence study publication-title: J Am Acad Dermatol – volume: 18 start-page: 517 issue: 2 year: 2019 end-page: 523 article-title: Comparative study of fractional Erbium: YAG laser vs combined therapy with topical steroid as an adjuvant treatment in melasma publication-title: J Cosmet Dermatol – volume: 49 start-page: 899 issue: 10 year: 2017 end-page: 907 article-title: Efficacy and safety of a novel picosecond laser using combination of 1 064 and 595 nm on patients with melasma: a prospective, randomized, multicenter, split‐face, 2% hydroquinone cream‐controlled clinical trial publication-title: Lasers Surg Med – volume: 25 start-page: 218 issue: 3 year: 2014 end-page: 222 article-title: Combination of fractional erbium‐glass laser and topical therapy in melasma resistant to triple‐combination cream publication-title: J Dermatolog Treat – volume: 6 start-page: 139 issue: 3 year: 2013 article-title: A randomised, open‐label, comparative study of tranexamic acid microinjections and tranexamic acid with microneedling in patients with melasma publication-title: J Cutan Aesthet Surg – volume: 75 start-page: 385 issue: 2 year: 2016 end-page: 392 article-title: Oral tranexamic acid (TA) in the treatment of melasma: a retrospective analysis publication-title: J Am Acad Dermatol – volume: 3 start-page: 124 issue: 4 year: 2019 end-page: 126 article-title: Topical tranexamic acid with microneedling in melasma publication-title: Acta Scientific Med Sci – volume: 33 start-page: 291 issue: 3 year: 2011 end-page: 295 article-title: Histochemical and immunohistochemical study in melasma: evidence of damage in the basal membrane publication-title: Am J Dermatopathol – volume: 25 start-page: 494 issue: 6 year: 1999 end-page: 497 article-title: Combination treatment of melasma with pulsed CO2 laser followed by Q‐switched alexandrite laser: a pilot study publication-title: Dermatol Surg – volume: 29 start-page: 163 issue: 3 year: 2009 end-page: 166 article-title: Effects of Chinese herbal medicine combined with He‐Ne laser on lipoperoxide and superoxide dismutase in chloasma patients publication-title: J Tradit Chin Med – volume: 25 start-page: 477 issue: 5 year: 2012 end-page: 480 article-title: Single‐session intense pulsed light combined with stable fixed‐dose triple combination topical therapy for the treatment of refractory melasma publication-title: Dermatol Ther – volume: 31 start-page: 991 issue: 5 year: 2016 end-page: 995 article-title: Efficacy of 694‐nm fractional Q‐switched ruby laser (QSRL) combined with sonophoresis on levorotatory vitamin C for treatment of melasma in Chinese patients publication-title: Lasers Med Sci – volume: 46 start-page: 111 issue: 2 year: 2007 end-page: 116 article-title: The vascular characteristics of melasma publication-title: J Dermatol Sci – volume: 30 start-page: 1 issue: 1 year: 2018 end-page: 7 article-title: Treatment of melasma with pulsed‐dye laser and 1,064‐nm Q‐switched Nd:YAG laser: a split‐face study publication-title: Ann Dermatol – volume: 82 start-page: 587 issue: 5 year: 2016 article-title: Combined vitamin C sonophoresis and neodymium‐doped yttrium aluminum garnet (NdYAG) laser for facial hyperpigmentation: an outcome observation study in Asian patients publication-title: Indian J Dermatol Venereol Leprol – volume: 3 start-page: 11 issue: 1 year: 2017 end-page: 20 article-title: A review of laser and light therapy in melasma publication-title: Int J Womens Dermatol – volume: 19 start-page: e228 issue: 8 year: 2010 end-page: e233 article-title: In vivo reflectance confocal microscopy detects pigmentary changes in melasma at a cellular level resolution publication-title: Exp Dermatol – volume: 20 start-page: 320 issue: 6 year: 2018 end-page: 325 article-title: Topical 3% tranexamic acid enhances the efficacy of 1064‐nm Q‐switched neodymium‐doped yttrium aluminum garnet laser in the treatment of melasma publication-title: J Cosmet Laser Ther – volume: 11 start-page: 28 issue: 4 year: 2018 end-page: 34 article-title: Dual effect of photobiomodulation on melasma: downregulation of hyperpigmentation and enhanced solar resistance‐A pilot study publication-title: J Clin Aesthet Dermatol – volume: 39 start-page: 435 issue: 3 Pt 1 year: 2013 end-page: 442 article-title: Oral tranexamic acid enhances the efficacy of low‐fluence 1064‐nm quality‐switched neodymium‐doped yttrium aluminum garnet laser treatment for melasma in Koreans: a randomized, prospective trial publication-title: Dermatol Surg – volume: 146 start-page: 228 issue: 2 year: 2002 end-page: 237 article-title: Melasma: histopathological characteristics in 56 Korean patients publication-title: Br J Dermatol – volume: 37 start-page: 224 issue: 2 year: 2011 end-page: 233 article-title: Sequential treatment with triple combination cream and intense pulsed light is more efficacious than sequential treatment with an inactive (control) cream and intense pulsed light in patients with moderate to severe melasma publication-title: Dermatol Surg – volume: 54 start-page: S272 issue: 5 Suppl 2 year: 2006 end-page: S281 article-title: Treatment of melasma publication-title: J Am Acad Dermatol – volume: 173 start-page: 209 issue: 1 year: 2015 end-page: 217 article-title: Evaluation of the efficacy of cysteamine 5% cream in the treatment of epidermal melasma: a randomized double‐blind placebo‐controlled trial publication-title: Br J Dermatol – volume: 28 start-page: 155 issue: 2 year: 2017 end-page: 159 article-title: A pilot study for triple combination therapy with a low‐fluence 1064 nm Q‐switched Nd:YAG laser, hydroquinone cream and oral tranexamic acid for recalcitrant Riehl's Melanosis publication-title: J Dermatolog Treat – volume: 25 start-page: 523 issue: 6 year: 2014 end-page: 528 article-title: A comparative study of low‐fluence 1064‐nm Q‐switched Nd:YAG laser with or without chemical peeling using Jessner's solution in melasma patients publication-title: J Dermatolog Treat – volume: 28 start-page: 13 issue: 1 year: 2018 end-page: 16 article-title: Efficacy of intense pulse light therapy and tripple combination cream versus intense pulse light therapy and tripple combination cream alone in epidermal melasma treatment publication-title: J Coll Physicians Surg Pak – volume: 31 start-page: 133 issue: 2 year: 2019 article-title: A face‐split study to evaluate the effects of microneedle radiofrequency with Q‐switched Nd:YAG laser for the treatment of melasma publication-title: Ann Dermatol – volume: 41 start-page: 457 issue: 4 year: 2015 end-page: 465 article-title: Treatment of melasma in men with low‐fluence Q‐switched neodymium‐doped yttrium‐aluminum‐garnet laser versus combined laser and glycolic acid peeling publication-title: Dermatol Surg – volume: 36 start-page: 909 issue: 6 year: 2010 end-page: 918 article-title: Low‐fluence Q‐switched neodymium‐doped yttrium aluminum garnet laser for melasma with pre‐ or post‐treatment triple combination cream publication-title: Dermatol Surg – volume: 17 start-page: 319 issue: 3 year: 2018 end-page: 327 article-title: Q‐switched Nd: YAG laser alone or with modified Jessner chemical peeling for treatment of mixed melasma in dark skin types: A comparative clinical, histopathological, and immunohistochemical study publication-title: J Cosmet Dermatol – volume: 96 issue: 19 year: 2017 article-title: Efficacy of functional microarray of microneedles combined with topical tranexamic acid for melasma publication-title: Medicine – volume: 19 start-page: 13 issue: 1 year: 2017 end-page: 17 article-title: Combination of fractional QSRL and IPL for melasma treatment in Chinese population publication-title: J Cosmet Laser Ther – volume: 6 start-page: 2 issue: 280 year: 2015 article-title: Efficacy of intradermal injection of tranexamic acid, topical silymarin and glycolic acid peeling in treatment of melasma: a comparative study publication-title: J Clin Exp Dermatol Res – volume: 34 start-page: 1099 issue: 6 year: 2019 end-page: 1105 article-title: Clinical efficacy of laser combined with menstrual regulation in the treatment of female melasma: a retrospective study publication-title: Lasers Med Sci – volume: 29 start-page: 59 issue: 1 year: 2003 end-page: 64 article-title: Combined ultrapulse CO2 laser and Q‐switched alexandrite laser compared with Q‐switched alexandrite laser alone for refractory melasma: split‐face design publication-title: Dermatol Surg – volume: 27 start-page: 373 issue: 4 year: 2015 end-page: 377 article-title: Topical tranexamic acid as an adjuvant treatment in melasma: side‐by‐side comparison clinical study publication-title: J Dermatol Treat – volume: 12 start-page: 18 year: 2012 article-title: The treatment of melasma by silymarin cream publication-title: BMC Dermatol – volume: 36 start-page: 864 issue: 8 year: 2011 end-page: 870 article-title: A randomized, observer‐blinded, comparison of combined 1064‐nm Q‐switched neodymium‐doped yttrium‐aluminium‐garnet laser plus 30% glycolic acid peel vs. laser monotherapy to treat melasma publication-title: Clin Exp Dermatol – volume: 12 start-page: 126 issue: 3 year: 2010 end-page: 131 article-title: Treatment of refractory melasma with the MedLite C6 Q‐switched Nd:YAG laser and alpha arbutin: a prospective study publication-title: J Cosmet Laser Ther – volume: 49 start-page: 20 issue: 1 year: 2017 end-page: 26 article-title: Retrospective analysis of the treatment of melasma lesions exhibiting increased vascularity with the 595‐nm pulsed dye laser combined with the 1927‐nm fractional low‐powered diode laser publication-title: Lasers Surg Med – volume: 15 start-page: 143 issue: 3 year: 2013 end-page: 149 article-title: A split‐face comparison of low‐fluence Q‐switched Nd: YAG laser plus 1550 nm fractional photothermolysis vs. Q‐switched Nd: YAG monotherapy for facial melasma in Asian skin publication-title: J Cosmet Laser Ther – volume: 9 start-page: 315 issue: 4 year: 2010 end-page: 322 article-title: The treatment of melasma with topical creams alone, CO2 fractional ablative resurfacing alone, or a combination of the two: a comparative study publication-title: J Drugs Dermatol – volume: 40 start-page: 748 issue: 7 year: 2014 end-page: 755 article-title: Combined use of monopolar radiofrequency and transdermal drug delivery in the treatment of melasma publication-title: Dermatol Surg – volume: 30 start-page: 352 issue: 4 year: 2019 end-page: 356 article-title: Combined treatment of melasma involving low‐fluence Q‐switched Nd:YAG laser and fractional microneedling radiofrequency publication-title: J Dermatol Treat – volume: 22 start-page: 373 issue: 4 year: 2010 article-title: What should be considered in treatment of melasma publication-title: Ann Dermatol – volume: 29 start-page: 1339 issue: 7 year: 2015 end-page: 1346 article-title: Low‐fluence Q‐switched Nd: YAG 1064‐nm laser and intense pulsed light for the treatment of melasma publication-title: J Eur Acad Dermatol Venereol – volume: 30 start-page: 159 issue: 1 year: 2015 end-page: 163 article-title: Treatment of melasma with mixed parameters of 1,064‐nm Q‐switched Nd:YAG laser toning and an enhanced effect of ultrasonic application of vitamin C: a split‐face study publication-title: Lasers Med Sci – ident: e_1_2_8_22_1 doi: 10.1111/jocd.12444 – ident: e_1_2_8_9_1 doi: 10.1097/01.dad.0000154419.18653.2e – ident: e_1_2_8_54_1 doi: 10.1111/acel.12298 – volume: 3 start-page: 124 issue: 4 year: 2019 ident: e_1_2_8_53_1 article-title: Topical tranexamic acid with microneedling in melasma publication-title: Acta Scientific Med Sci – ident: e_1_2_8_19_1 doi: 10.3109/09546634.2012.671911 – volume: 9 start-page: 315 issue: 4 year: 2010 ident: e_1_2_8_20_1 article-title: The treatment of melasma with topical creams alone, CO2 fractional ablative resurfacing alone, or a combination of the two: a comparative study publication-title: J Drugs Dermatol – ident: e_1_2_8_35_1 doi: 10.1046/j.1524-4725.1999.08248.x – ident: e_1_2_8_17_1 doi: 10.1111/j.1524-4725.2010.01523.x – ident: e_1_2_8_12_1 doi: 10.1111/bjd.13424 – ident: e_1_2_8_4_1 doi: 10.1111/bjd.12536 – ident: e_1_2_8_24_1 doi: 10.1097/DSS.0000000000000304 – ident: e_1_2_8_14_1 doi: 10.1111/dsu.12060 – ident: e_1_2_8_39_1 doi: 10.1002/lsm.22518 – ident: e_1_2_8_34_1 doi: 10.5021/ad.2018.30.1.1 – ident: e_1_2_8_13_1 doi: 10.1016/j.jaad.2016.03.001 – ident: e_1_2_8_38_1 doi: 10.1097/DSS.0000000000000652 – ident: e_1_2_8_51_1 doi: 10.1097/MD.0000000000006897 – volume: 11 start-page: 28 issue: 4 year: 2018 ident: e_1_2_8_59_1 article-title: Dual effect of photobiomodulation on melasma: downregulation of hyperpigmentation and enhanced solar resistance‐A pilot study publication-title: J Clin Aesthet Dermatol – ident: e_1_2_8_5_1 doi: 10.1111/j.1600-0625.2009.01057.x – ident: e_1_2_8_15_1 doi: 10.1080/09546634.2016.1187706 – ident: e_1_2_8_28_1 doi: 10.1007/s10103-016-1938-3 – ident: e_1_2_8_37_1 doi: 10.1002/lsm.22735 – ident: e_1_2_8_42_1 doi: 10.1111/j.1524-4725.2010.01849.x – ident: e_1_2_8_2_1 doi: 10.1016/j.jaad.2005.12.039 – ident: e_1_2_8_32_1 doi: 10.1111/jocd.12751 – ident: e_1_2_8_33_1 doi: 10.3109/14764172.2013.769274 – ident: e_1_2_8_48_1 doi: 10.5021/ad.2019.31.2.133 – ident: e_1_2_8_55_1 doi: 10.22270/jddt.v9i2.2453 – ident: e_1_2_8_47_1 doi: 10.1080/09546634.2018.1516858 – ident: e_1_2_8_52_1 doi: 10.4103/0974-2077.118403 – ident: e_1_2_8_21_1 doi: 10.1111/j.1365-2230.2011.04150.x – ident: e_1_2_8_31_1 doi: 10.3109/14764172.2010.487910 – ident: e_1_2_8_10_1 doi: 10.1097/DAD.0b013e3181ef2d45 – ident: e_1_2_8_44_1 doi: 10.1097/DSS.0000000000000057 – ident: e_1_2_8_23_1 doi: 10.3109/09546634.2013.848261 – volume: 40 start-page: 748 issue: 7 year: 2014 ident: e_1_2_8_50_1 article-title: Combined use of monopolar radiofrequency and transdermal drug delivery in the treatment of melasma publication-title: Dermatol Surg – ident: e_1_2_8_41_1 doi: 10.1111/j.1529-8019.2012.01530.x – volume: 37 start-page: 126 issue: 1 year: 2011 ident: e_1_2_8_18_1 article-title: Low‐fluence Q‐switched neodymium‐doped yttrium aluminum garnet laser for melasma with pre‐ or post‐treatment triple combination cream publication-title: Dermatol Surg – ident: e_1_2_8_25_1 doi: 10.1002/lsm.21156 – volume: 6 start-page: 2 issue: 280 year: 2015 ident: e_1_2_8_58_1 article-title: Efficacy of intradermal injection of tranexamic acid, topical silymarin and glycolic acid peeling in treatment of melasma: a comparative study publication-title: J Clin Exp Dermatol Res – ident: e_1_2_8_11_1 doi: 10.1016/j.ijwd.2017.01.004 – ident: e_1_2_8_57_1 doi: 10.1186/1471-5945-12-18 – ident: e_1_2_8_27_1 doi: 10.1007/s10103-014-1608-2 – ident: e_1_2_8_26_1 doi: 10.4103/0378-6323.182806 – ident: e_1_2_8_6_1 doi: 10.1016/j.jdermsci.2007.01.009 – ident: e_1_2_8_3_1 doi: 10.5021/ad.2010.22.4.373 – ident: e_1_2_8_16_1 doi: 10.1080/14764172.2018.1427869 – ident: e_1_2_8_8_1 doi: 10.1046/j.0007-0963.2001.04556.x – ident: e_1_2_8_30_1 doi: 10.1007/s10103-018-02698-w – ident: e_1_2_8_40_1 doi: 10.29271/jcpsp.2018.01.13 – ident: e_1_2_8_29_1 doi: 10.1016/S0254-6272(09)60056-X – ident: e_1_2_8_45_1 doi: 10.1111/jdv.12854 – ident: e_1_2_8_36_1 doi: 10.1046/j.1524-4725.2003.29009.x – ident: e_1_2_8_43_1 doi: 10.3109/09546634.2015.1115812 – ident: e_1_2_8_46_1 doi: 10.1080/14764172.2016.1228980 – ident: e_1_2_8_7_1 doi: 10.1016/S0190-9622(81)70071-9 – ident: e_1_2_8_49_1 doi: 10.1080/14764172.2017.1342036 – ident: e_1_2_8_56_1 doi: 10.1016/j.bmc.2019.03.013 |
| SSID | ssj0017915 |
| Score | 2.3081667 |
| SecondaryResourceType | review_article |
| Snippet | Background
Melasma is an acquired disorder of hyperpigmentation, affecting a million individuals worldwide. Energy‐based devices (EBDs) employed to treat... Melasma is an acquired disorder of hyperpigmentation, affecting a million individuals worldwide. Energy-based devices (EBDs) employed to treat melasma include... |
| SourceID | proquest pubmed crossref wiley |
| SourceType | Aggregation Database Index Database Enrichment Source Publisher |
| StartPage | 461 |
| SubjectTerms | Combined Modality Therapy Humans Hyperpigmentation Laser Therapy Low-Level Light Therapy Melanosis - therapy Treatment Outcome |
| Title | A review of combined treatments for melasma involving energy‐based devices and proposed pathogenesis‐oriented combinations |
| URI | https://onlinelibrary.wiley.com/doi/abs/10.1111%2Fjocd.14110 https://www.ncbi.nlm.nih.gov/pubmed/33794033 https://www.proquest.com/docview/2508564668 |
| Volume | 21 |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV3Nb9MwFLfKJk27oPFdBsgILjAZOV9Oeixb0RgqO7Ch3SLbcWilJanS9rIzfzjPduKkrEPAJY3c1Kn6-_XlfT-E3vo5PPa5n5NQZJKEeaJIwhnXwlCGI80grl0D06_s9DI8u4quBoOfvayl9Up8kDdb60r-B1VYA1x1lew_IOs2hQU4B3zhCAjD8a8wHvcqT2B_MHJBfXSp46bTwlGhQD8u-NG8BEFkvAfKlPsR_fzKdNGUFhVNv4BqUelFPaa4-qGl4HxJKt0JWeul9g49D99tnVZWy0JXRcK2WhXecNlP1azmYt6FHboo0Edek8_X1hU7yYGTnZt_aac9f5upGc-U811_qWorL8fFvO57LsDopS4LRFlpG8YB8T07LKIVx7ZguqGd35Otoe3afpfMr2QGYt-zSbI98BeFQT8IQPJQ23Tjtw7b7Vv30K4fxzrYv3v-fTI5cdGoeORFTWtbkwXmbrWP9toPb-o1t4yVTdvHKC8XB-h-gxAeWwo9QANVPkR70yav4hG6GWPLJFzluGUS7piEgUm4YRJ2TMJ9JuGGSRiYhFsm4a1Mwn0mPUaXnyYXx6ekmcpBZOCPKPH0BDJJgzxgnol6g8YfAwMCIUXmSz8PGQ8olcJjXEYZZZwKGrOQURlJlWTBE7RTVqV6hrCMZSA8HgvBQSvPJLxyykDhjCKZM8qH6F37m6ayaVmvJ6dcp850BShSA8UQvXHXLmyjlq1XvW6hSUGO6uAYL1W1XqZgCiQRfEuWDNFTi5nbp8V4iN4bEP9wg_Ts_PjEnD2_c5tDtN_9HV6gnVW9Vi9BtV2JVw3zfgEsSKqu |
| linkProvider | Ovid |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=A+review+of+combined+treatments+for+melasma+involving+energy-based+devices+and+proposed+pathogenesis-oriented+combinations&rft.jtitle=Journal+of+cosmetic+dermatology&rft.au=Mehrabi%2C+Joseph+N&rft.au=Bar-Ilan%2C+Efrat&rft.au=Wasim%2C+Shehadeh&rft.au=Koren%2C+Amir&rft.date=2022-02-01&rft.eissn=1473-2165&rft.volume=21&rft.issue=2&rft.spage=461&rft_id=info:doi/10.1111%2Fjocd.14110&rft_id=info%3Apmid%2F33794033&rft.externalDocID=33794033 |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1473-2130&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1473-2130&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1473-2130&client=summon |